AU2018358157B2 - Modulators of the integrated stress pathway - Google Patents

Modulators of the integrated stress pathway Download PDF

Info

Publication number
AU2018358157B2
AU2018358157B2 AU2018358157A AU2018358157A AU2018358157B2 AU 2018358157 B2 AU2018358157 B2 AU 2018358157B2 AU 2018358157 A AU2018358157 A AU 2018358157A AU 2018358157 A AU2018358157 A AU 2018358157A AU 2018358157 B2 AU2018358157 B2 AU 2018358157B2
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018358157A
Other languages
English (en)
Other versions
AU2018358157A1 (en
Inventor
Michael J. Dart
Jennifer M. Frost
Kathleen Ann MARTIN
Carmela SIDRAUSKI
Yunsong Tong
Zhaoming Xiong
Xiangdong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Calico Life Sciences LLC
Original Assignee
AbbVie Inc
Calico Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Calico Life Sciences LLC filed Critical AbbVie Inc
Publication of AU2018358157A1 publication Critical patent/AU2018358157A1/en
Application granted granted Critical
Publication of AU2018358157B2 publication Critical patent/AU2018358157B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2018358157A 2017-11-02 2018-11-02 Modulators of the integrated stress pathway Active AU2018358157B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762580802P 2017-11-02 2017-11-02
US62/580,802 2017-11-02
US201862643073P 2018-03-14 2018-03-14
US62/643,073 2018-03-14
PCT/US2018/058965 WO2019090082A1 (en) 2017-11-02 2018-11-02 Modulators of the integrated stress pathway

Publications (2)

Publication Number Publication Date
AU2018358157A1 AU2018358157A1 (en) 2020-06-11
AU2018358157B2 true AU2018358157B2 (en) 2023-03-09

Family

ID=64661438

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018358157A Active AU2018358157B2 (en) 2017-11-02 2018-11-02 Modulators of the integrated stress pathway

Country Status (9)

Country Link
US (1) US20210205277A1 (enExample)
EP (1) EP3704096A1 (enExample)
JP (1) JP7324196B2 (enExample)
CN (1) CN112204012B (enExample)
AU (1) AU2018358157B2 (enExample)
BR (1) BR112020008825A2 (enExample)
CA (1) CA3080964A1 (enExample)
MX (1) MX2020004519A (enExample)
WO (1) WO2019090082A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094233B (zh) 2017-08-09 2024-03-15 戴纳立制药公司 化合物、组合物及方法
PT3676297T (pt) 2017-09-01 2023-08-29 Denali Therapeutics Inc Compostos, composições e métodos
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
RU2020122711A (ru) 2017-12-13 2022-01-17 ПРАКСИС БАЙОТЕК ЭлЭлСи Ингибиторы пути интегрированной реакции на стресс
SG11202011014VA (en) 2018-06-05 2020-12-30 Praxis Biotech LLC Inhibitors of integrated stress response pathway
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CA3129609A1 (en) 2019-02-13 2020-08-20 Denali Therapeutics Inc. Eukaryotic initiation factor 2b modulators
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
AU2020261234A1 (en) 2019-04-23 2021-11-11 Evotec International Gmbh Modulators of the integrated stress response pathway
EA202192900A1 (ru) 2019-04-23 2022-03-18 Эвотек Интернешнл Гмбх Модуляторы пути интегрированной реакции на стресс
CA3142748A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
KR20220133252A (ko) * 2020-01-28 2022-10-04 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절자
JP2023517944A (ja) 2020-03-11 2023-04-27 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合的ストレス応答経路の調節因子
US20230391763A1 (en) * 2020-10-22 2023-12-07 Evotec International Gmbh Modulators of the integrated stress response pathway
AU2021366303A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
CN116406359A (zh) * 2020-11-19 2023-07-07 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的双环[1.1.1]戊烷化合物
CN115453012B (zh) * 2022-10-21 2023-05-12 山东百诺医药股份有限公司 一种同时测定氢溴酸伏硫西汀中多个位置异构体的反相hplc方法
CN120187707A (zh) * 2022-11-21 2025-06-20 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其合成方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US162A (en) 1837-04-17 Island
US5212A (en) 1847-07-31 Richard m
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CN100471854C (zh) * 2002-12-20 2009-03-25 麦克公司 用作11-β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
WO2011087758A1 (en) * 2009-12-22 2011-07-21 H. Lundbeck A/S Adamantyl amide derivatives and uses of same
WO2015038778A1 (en) * 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
JP2015199722A (ja) * 2014-04-02 2015-11-12 大日本住友製薬株式会社 イミダゾール誘導体からなる医薬
TW201722958A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160096800A1 (en) * 2013-03-15 2016-04-07 The Regents Of The University Of California Modulators of the eif2alpha pathway

Also Published As

Publication number Publication date
JP2021501787A (ja) 2021-01-21
CN112204012A (zh) 2021-01-08
US20210205277A1 (en) 2021-07-08
WO2019090082A1 (en) 2019-05-09
MX2020004519A (es) 2020-11-09
AU2018358157A1 (en) 2020-06-11
EP3704096A1 (en) 2020-09-09
BR112020008825A2 (pt) 2020-10-20
CA3080964A1 (en) 2019-05-09
CN112204012B (zh) 2023-12-26
JP7324196B2 (ja) 2023-08-09

Similar Documents

Publication Publication Date Title
AU2018358157B2 (en) Modulators of the integrated stress pathway
AU2023203860B2 (en) Modulators of the integrated stress pathway
AU2023201399B2 (en) Modulators of the integrated stress pathway
AU2018358160B2 (en) Modulators of the integrated stress pathway
AU2018360854B2 (en) Modulators of the integrated stress pathway
EP3704089B1 (en) Modulators of the integrated stress pathway
EP3704098B1 (en) Modulators of the integrated stress pathway
CA3138182A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
HK40037526A (en) Modulators of the integrated stress pathway
HK40037526B (en) Modulators of the integrated stress pathway

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)